Classical homocystinuria (HCU) is an inborn error of sulfur amino acid metabolism caused by deficient activity of cystathionine β-synthase (CBS), resulting in an accumulation of homocysteine and a concomitant decrease of cystathionine and cysteine in blood and tissues. In mice, the complete lack of CBS is neonatally lethal. In this study, newborn CBS-knockout (KO) mice were treated with recombinant polyethyleneglycolylated human truncated CBS (PEG-CBS). Full survival of the treated KO mice, along with a positive impact on metabolite levels in plasma, liver, brain, and kidneys, was observed. The PEG-CBS treatment prevented an otherwise fatal liver disease characterized by steatosis, death of hepatocytes, and ultrastructural abnormalities of endoplasmic reticulum and mitochondria. Furthermore, treatment of the KO mice for 5 mo maintained the plasma metabolite balance and completely prevented osteoporosis and changes in body composition that characterize both the KO model and human patients. These findings argue that early treatment of patients with HCU with PEG-CBS may prevent clinical symptoms of the disease possibly without the need of dietary protein restriction.-Majtan, T., Hůlková, H., Park, I., Krijt, J., Kožich, V., Bublil, E. M., Kraus, J. P. Enzyme replacement prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria.

Department of Pediatrics University of Colorado School of Medicine Aurora Colorado USA

Department of Pediatrics University of Colorado School of Medicine Aurora Colorado USA;

Institute of Inherited Metabolic Disorders Charles University 1st Faculty of Medicine and General University Hospital Prague Czech Republic

Institute of Pathology Charles University 1st Faculty of Medicine and General University Hospital Prague Czech Republic; and

Orphan Technologies Limited Rapperswil Switzerland

Zobrazit více v PubMed

Mudd S. H., Levy H. L., Kraus J. P. (2001) Disorders of transsulfuration. In The Metabolic and Molecular Bases of Inherited Disease (Scriver C. R., Beaudet A. L., Sly W. S., Valle D., Childs B., Kinzler K., Vogelstein B., eds), pp. 2007–2056, McGraw-Hill, New York

Moorthie S., Cameron L., Sagoo G. S., Bonham J. R., Burton H. (2014) Systematic review and meta-analysis to estimate the birth prevalence of five inherited metabolic diseases. J. Inherit. Metab. Dis. 37, 889–898 PubMed

Majtan T., Pey A. L., Ereño-Orbea J., Martínez-Cruz L. A., Kraus J. P. (2016) Targeting cystathionine beta-synthase misfolding in homocystinuria by small ligands: state of the art and future directions. Curr. Drug Targets 17, 1455–1470 PubMed

Morris A. A., Kožich V., Santra S., Andria G., Ben-Omran T. I., Chakrapani A. B., Crushell E., Henderson M. J., Hochuli M., Huemer M., Janssen M. C., Maillot F., Mayne P. D., McNulty J., Morrison T. M., Ogier H., O’Sullivan S., Pavlíková M., de Almeida I. T., Terry A., Yap S., Blom H. J., Chapman K. A. (2017) Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J. Inherit. Metab. Dis. 40, 49–74 PubMed PMC

Bublil E. M., Majtan T., Park I., Carrillo R. S., Hůlková H., Krijt J., Kožich V., Kraus J. P. (2016) Enzyme replacement with PEGylated cystathionine β-synthase ameliorates homocystinuria in murine model. J. Clin. Invest. 126, 2372–2384 PubMed PMC

Watanabe M., Osada J., Aratani Y., Kluckman K., Reddick R., Malinow M. R., Maeda N. (1995) Mice deficient in cystathionine β-synthase: animal models for mild and severe homocyst(e)inemia. Proc. Natl. Acad. Sci. USA 92, 1585–1589 PubMed PMC

Majtan T., Park I., Carrillo R. S., Bublil E. M., Kraus J. P. (2017) Engineering and characterization of an enzyme replacement therapy for classical homocystinuria. Biomacromolecules 18, 1747–1761 PubMed

Maclean K. N., Sikora J., Kožich V., Jiang H., Greiner L. S., Kraus E., Krijt J., Crnic L. S., Allen R. H., Stabler S. P., Elleder M., Kraus J. P. (2010) Cystathionine beta-synthase null homocystinuric mice fail to exhibit altered hemostasis or lowering of plasma homocysteine in response to betaine treatment. Mol. Genet. Metab. 101, 163–171 PubMed PMC

Allen R. H., Stabler S. P., Lindenbaum J. (1993) Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolism. Metabolism 42, 1448–1460 PubMed

Krijt J., Dutá A., Kozich V. (2009) Determination of S-adenosylmethionine and S-adenosylhomocysteine by LC-MS/MS and evaluation of their stability in mice tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 2061–2066 PubMed PMC

Kožich V., Krijt J., Sokolová J., Melenovská P., Ješina P., Vozdek R., Majtán T., Kraus J. P. (2016) Thioethers as markers of hydrogen sulfide production in homocystinurias. Biochimie 126, 14–20 PubMed

Komrower G. M., Lambert A. M., Cusworth D. C., Westall R. G. (1966) Dietary treatment of homocystinuria. Arch. Dis. Child. 41, 666–671 PubMed PMC

Barber G. W., Spaeth G. L. (1967) Pyridoxine therapy in homocystinuria. Lancet 1, 337

Smolin L. A., Benevenga N. J., Berlow S. (1981) The use of betaine for the treatment of homocystinuria. J. Pediatr. 99, 467–472 PubMed

Walter J. H., Wraith J. E., White F. J., Bridge C., Till J. (1998) Strategies for the treatment of cystathionine β-synthase deficiency: the experience of the Willink Biochemical Genetics Unit over the past 30 years. Eur. J. Pediatr. 157(Suppl 2), S71–S76 PubMed

Vitvitsky V., Dayal S., Stabler S., Zhou Y., Wang H., Lentz S. R., Banerjee R. (2004) Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R39–R46 PubMed

Dickinson D. A., Forman H. J. (2002) Glutathione in defense and signaling: lessons from a small thiol. Ann. N. Y. Acad. Sci. 973, 488–504 PubMed

Robert K., Nehmé J., Bourdon E., Pivert G., Friguet B., Delcayre C., Delabar J. M., Janel N. (2005) Cystathionine beta synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver. Gastroenterology 128, 1405–1415 PubMed

Mack C. L., Emerick K. M., Kovarik P., Charrow J. (2001) Early speech delay and hepatitis as presenting signs of homocystinuria. J. Pediatr. Gastroenterol. Nutr. 33, 221–223 PubMed

Gaull G. E., Schaffner F. (1971) Electron microscopic changes in hepatocytes of patients with homocystinuria. Pediatr. Res. 5, 23–32

Gaull G., Sturman J. A., Schaffner F. (1974) Homocystinuria due to cystathionine synthase deficiency: enzymatic and ultrastructural studies. J. Pediatr. 84, 381–390 PubMed

Schedewie H., Willich E., Gröbe H., Schmidt H., Müller K. M. (1973) Skeletal findings in homocystinuria: a collaborative study. Pediatr. Radiol. 1, 12–23 PubMed

Parrot F., Redonnet-Vernhet I., Lacombe D., Gin H. (2000) Osteoporosis in late-diagnosed adult homocystinuric patients. J. Inherit. Metab. Dis. 23, 338–340 PubMed

Wilcken D. E. L., Wilcken B. (1997) The natural history of vascular disease in homocystinuria and the effects of treatment. J. Inherit. Metab. Dis. 20, 295–300 PubMed

Kraus J. P., Hasek J., Kozich V., Collard R., Venezia S., Janosíková B., Wang J., Stabler S. P., Allen R. H., Jakobs C., Finn C. T., Chien Y. H., Hwu W. L., Hegele R. A., Mudd S. H. (2009) Cystathionine gamma-lyase: clinical, metabolic, genetic, and structural studies. Mol. Genet. Metab. 97, 250–259 PubMed PMC

Huemer M., Kožich V., Rinaldo P., Baumgartner M. R., Merinero B., Pasquini E., Ribes A., Blom H. J. (2015) Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines. J. Inherit. Metab. Dis. 38, 1007–1019 PubMed PMC

Deciphering pathophysiological mechanisms underlying cystathionine beta-synthase-deficient homocystinuria using targeted metabolomics, liver proteomics, sphingolipidomics and analysis of mitochondrial function

Recent therapeutic approaches to cystathionine beta-synthase-deficient homocystinuria

Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria